The Endocrine Society's Guidelines for the Pharmacologic Management of Obesity, advises clinicians to "treat weight first" to mitigate or eliminate its related comorbidities and complications including type 2 diabetes. Learn more about this dynamic program, the benefits of weight reduction on diabetes, and how to earn 1.5 AMA PRA Category 1 CME credits.
- Posted June 15, 2016 by Beta Cells in Diabetes Staff
- Posted March 15, 2016 by Beta Cells in Diabetes Staff
Earn up to 0.75 AMA PRA Category 1 CME credits for the Hypoglycemia Risk in Type 2 Diabetes interactive case study that allows you to follow a patient through key stages and decision points in his diabetes care. Use the hypoglycemia risk calculator with the case study to help determine the patient’s hypoglycemia risk at different points in his diabetes care.
- Posted August 4, 2014 by John L. Leahy, MD
Is there actually a proven benefit of intensive blood glucose control in patients who have diabetes, and if there is what actually is that benefit? In this 8-minute podcast, Drs. Jack Leahy and Doron Schneider answer this question based on data from The Diabetes Control and Complications study.
- Posted June 24, 2014 by Beta Cells in Diabetes Staff
The future of diabetes may be restoring beta-cell differentiation as opposed to promoting insulin production, says award-winning researcher at the 2014 ICE/ENDO conference in Chicago.
- Posted June 18, 2014 by John L. Leahy, MD
The results of the Diabetes Control and Complications Trial (DCCT) showed an outstanding benefit of almost 70 percent reduction in microvascular disease when driving down A1C to 7, but also showed a higher frequency of hypoglycemia -- events that patients don’t forget. "It was clear intensive therapy back then came with a significant price."
- Posted February 14, 2014 by Doron Schneider, MD, FACPHow should primary care physicians who treat diabetes patients address the challenges posed by new cholesterol guidelines from the ACC and AHA? This blog post intends to raise awareness about the guidelines and inject a discussion point around the issues of the “baseline LDL,” repeatedly checking LDL levels, and monitoring adherence.
- Posted December 17, 2013 by Jay Shubrook, DO, FACOFP, FAAFPPrimary care physicians must balance many medical problems at once. The subspecialist has experience with rarer forms of diabetes and complications that most primary care physicians only read about. Both knowledge and experience sets are needed for an effective team approach.
- Posted November 19, 2013 by Doron Schneider, MD, FACP
Obstructive sleep apnea is a common and underdiagnosed condition in patients with type 2 diabetes. This blog post explores what is known about the underlying mechanism that may relate sleep apnea to diabetes.
- Posted August 6, 2013 by Irl B. Hirsch, MDOver the past six months we have had more questions than answers about the risk of incretin therapy (DPP-4 inhibitors and GLP-1 agonists) and the increased risks for both pancreatitis and pancreatic carcinoma. The discussion seems to have resolved to an interim and perhaps temporary conclusion based on the recent American Diabetes Association Scientific Sessions in Chicago in June.At that conference Dr.
- Page 1 of 6